ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0016525;negative regulation of angiogenesis;8.0;0.811012628672052;0.780506314336026;9.32314260294094;151.1079732353669;5.192106149009898;0.005057447875840929;0.6405245499179943;[FASLG, PRL, HHEX, CCR2, HGS, CX3CR1, PLK2, TIE1, TEK]
GO:2000481;positive regulation of cAMP-dependent protein kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1426.5997261217476;8.16763571524637;0.0477470089768964;0.8658135829017477;[ADRB2]
GO:0008584;male gonad development;5.0;1.0;0.7902410118609202;9.628524252492122;50.96471695749156;5.2552850506314295;0.001705743211299806;0.5589965337459591;[HMGB2, PDGFRB, LHCGR, BIK, INHBA, NASP, MSH2, KIT]
GO:0035162;embryonic hemopoiesis;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;36.11381869205153;6.832634648514029;0.0012086970112962418;0.6725415662651573;[KIT]
GO:0032693;negative regulation of interleukin-10 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.943860283624253;0.002184000309729388;0.6782296504172152;[CD274, PRG2, LILRB1, PDCD1LG2, FCGR2B, DLL1]
GO:0032570;response to progesterone;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;105.99106082751567;6.166155715036245;0.0035474254201351726;0.6384578026126634;[GABRB1, TGFB1, CAV1, PTGER2, CLDN4, TLR2]
GO:1901224;positive regulation of NIK/NF-kappaB signaling;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;238.82315740091596;5.572381008289503;0.007993196151321231;0.6599718239061428;[HAVCR2, ACTN4, CHI3L1, TLR7, TLR4, TLR2, TNFSF14, TNFRSF10B, NLRP12, IL18R1]
GO:0007257;activation of JUN kinase activity;14.0;1.0;0.9759193652572005;9.628524252492122;8640.54909511404;6.088194173566533;0.2891914022241413;0.7872698984233759;[TNFSF11, MAP4K1, PKN1]
GO:0046854;phosphatidylinositol phosphorylation;8.0;1.0;0.875;9.628524252492122;218.7418113453505;5.049685808968129;0.007321091570879569;0.6332411671050352;[SLA2, FGF5, IMPA2, PDGFRB, GAB1, BTC, KIT, HBEGF, CD19, TRAT1, EGF, CD28]
GO:0051091;positive regulation of DNA binding transcription factor activity;11.0;0.811012628672052;0.8379352666656883;9.431813958246067;277.8307104044464;4.2636448815154875;0.00929874384583087;0.650471949850128;[PYCARD, AKT1, TNFSF11, BTK, S100A8, BEX1, TNFRSF11A, NLRP3, TGFB1, JUP, CD36, ANXA3, NFAM1, KIT, TLR4, LTF, TLR2, NLRC4]
GO:0051092;positive regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.4401483168805;4.8283137373023015;0.009352610284359957;0.6950405016553352;[PYCARD, TNFSF11, BTK, S100A8, TNFRSF11A, NLRP3, TGFB1, CD36, TLR4, LTF, TLR2, NLRC4]
GO:0071380;cellular response to prostaglandin E stimulus;8.0;1.0;0.875;9.628524252492122;704.3614414198233;6.943860283624253;0.023574343560179453;0.7301093378270707;[P2RY6, PTGER2, AKT1, PTGDR]
GO:0021795;cerebral cortex cell migration;7.0;0.7671156992804218;0.7344772148974115;9.223059144383958;22.93064785239865;6.641579411751319;7.67468147376534E-4;0.6905700452391912;[CX3CR1, NRP1]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[NRP1, CDH5, C3AR1, GHSR, ANXA3, GAB1, ADAM12, AGTR1, CHI3L1, ENG, CX3CR1, C5AR1, PTGS2, DLL1, CXCR2, JUP, PLK2, TNFSF12, LRG1, TEK]
GO:0072583;clathrin-dependent endocytosis;7.0;0.8436909121759173;0.7727648213451592;9.223059144383958;30.046907922432062;6.558197802812269;0.0010056429677022863;0.6863059058804069;[DLL1, AP2M1]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[, LRRK2, GHR, PROK2, TNFSF11, MAP4K1, MAP2K2, DUSP6, KIT, TLR4, C5AR1, FPR1, CXCR4, TGFA, IQGAP3, DRD4, EGF, CSPG4, PKN1]
GO:0048246;macrophage chemotaxis;8.0;1.0;0.875;9.628524252492122;95.91852822164125;7.212124270218933;0.0032103068185073717;0.7438283705770736;[CX3CR1, LGALS3, EDNRB, NUP85, AZU1]
GO:0001701;in utero embryonic development;7.0;1.0;0.8509193652572005;9.628524252492122;22.496195207419138;4.63541007117781;7.529274083310655E-4;0.5879744518658467;[MSH2, MAFF, PTPRR, TMEM100, HHEX, TIE1]
GO:0001947;heart looping;7.0;1.0;0.8509193652572005;9.628524252492122;47.98143023837329;5.71663061713405;0.001605895289594654;0.6432681208679463;[DLL1, MEF2C, ENG]
GO:2000353;positive regulation of endothelial cell apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;129.82178199018807;6.943860283624253;0.00434501821119318;0.7513499630073597;[FASLG]
GO:0097527;necroptotic signaling pathway;5.0;1.0;0.7902410118609202;9.628524252492122;23.17027026302992;7.9853141584524145;7.75488093814194E-4;0.6986103492792611;[FASLG]
GO:2001206;positive regulation of osteoclast development;10.0;1.0;0.9152410118609203;9.628524252492122;1248.090164263488;8.390779266560578;0.04177245458967596;0.8443458537639685;[TNFSF11]
GO:0019367;fatty acid elongation, saturated fatty acid;10.0;1.0;0.9152410118609203;9.628524252492122;363.0266052285773;7.8311634786251565;0.012150173774267114;0.8157270763441555;[ELOVL4, ELOVL6]
GO:0032689;negative regulation of interferon-gamma production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.343086423195323;0.002184000309729388;0.647506047256038;[CD274, LILRB1, INHBA, PDCD1LG2, TLR4, HAVCR2]
GO:0034626;fatty acid elongation, polyunsaturated fatty acid;11.0;1.0;0.9324289523296623;9.628524252492122;363.71975240913724;7.8311634786251565;0.012173372786608494;0.8329150168128974;[ELOVL4, ELOVL6]
GO:0034625;fatty acid elongation, monounsaturated fatty acid;11.0;1.0;0.9324289523296623;9.628524252492122;363.71975240913724;7.8311634786251565;0.012173372786608494;0.8329150168128974;[ELOVL4, ELOVL6]
GO:0032687;negative regulation of interferon-alpha production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;84.82850979692678;7.9853141584524145;0.00283913388220078;0.7592887026755414;[HAVCR2]
GO:0071812;positive regulation of fever generation by positive regulation of prostaglandin secretion;11.0;1.0;0.9324289523296623;9.628524252492122;762.7474768735852;9.083926447120524;0.025528471622796402;0.8969813732811862;[TNFSF11, TNFRSF11A]
GO:0030148;sphingolipid biosynthetic process;7.0;0.6913464685778243;0.6965925995461126;8.992535485772125;238.8284648682076;5.288437257948329;0.007993373787475071;0.6213702925661609;[ELOVL4, ELOVL6, P2RX1]
GO:2000491;positive regulation of hepatic stellate cell activation;6.0;1.0;0.8231203125901445;9.628524252492122;58.82470762909909;8.390779266560578;0.001968810025546158;0.7522251544931926;[PDGFRB, MYB]
GO:0065003;protein-containing complex assembly;4.0;0.45485133202666184;0.4774256660133309;6.058991556010752;36.471478728154885;2.4440506132939883;0.0012206675708314864;0.3749888620238313;[, NUP107, CLDN3, PDGFC, ABCA1, JUP, ARHGAP6, CHAF1B, CHAF1A, KCND2, ARG1, F5, SLC7A7, HLA-DMA, CENPK, CENPL, KCNG2, GMNN, RUVBL1, OLFM4, BLM, LIN7A, HLA-DRA, LRRK2, ACPP, HM13, IL2RB, CCNH, TCL1A, TNFSF11, FBXO5, TGFA, PTK2, CD3G, CD3E, RPA1, RPA3, H1FX, CAV1, HMGA1, NASP, TCF4, HMGB2, NUP62, NUP54, FBP1, SAMHD1, EGF, TEK, CDA, NUP205, BRD2, GSN, GTF2H1, DACH1, TLE4, NACC2, MCM2, NLGN1, NLRC4, RAD51, P2RX1, PPP2R1A, TLN1, MGST1, CD79B, CD79A, RAD51C, KNTC1, CHRNB4, ADRB2, NLRP3, TGFB1, DNM2, TGFBR3, COLEC12, HIST1H2BK, REPS2]
GO:0036120;cellular response to platelet-derived growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.781341354126479;0.003262744749111514;0.6699184248047958;[PDGFRB]
GO:1904504;positive regulation of lipophagy;9.0;1.0;0.896240625180289;9.628524252492122;315.93368011590877;8.16763571524637;0.0105740159516271;0.8139338954918922;[ADRB2]
GO:0002371;dendritic cell cytokine production;4.0;0.8933024483968273;0.6966512241984136;9.405380701177911;31.58806594444361;9.777073627680469;0.0010572241397468415;0.75;[KIT]
GO:0008354;germ cell migration;5.0;0.9326813400603323;0.7565816818910864;9.510741216835738;40.540081573954176;7.57984905034425;0.0013568400465755524;0.6778748447945537;[TGFB1, CXADR, KIT]
GO:0042267;natural killer cell mediated cytotoxicity;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;47.356962503066434;6.7325511899570465;0.001584994916478408;0.6674232935401965;[KLRK1, SLAMF7, KIR3DL1]
GO:0042269;regulation of natural killer cell mediated cytotoxicity;8.0;0.7671156992804218;0.7585578496402109;9.292052015870908;75.65119118824865;6.063501560976162;0.0025319772874188478;0.6850877518099798;[CLEC12B, IL18RAP, KLRK1, HAVCR2, LAG3, SH2D1A, LILRB1, NCR1, CEACAM1]
GO:0045540;regulation of cholesterol biosynthetic process;9.0;0.8933024483968273;0.8428918493787028;9.4949928598676;116.98845768213258;6.039404009397101;0.0039154983958446;0.705096027081865;[ELOVL6, POR, SCD, RAN]
GO:0048015;phosphatidylinositol-mediated signaling;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;26.42836680105094;5.649939242635378;8.845336528452411E-4;0.6398575208746181;[PTAFR, AKT1, KCNH1, PDGFRB, GSN]
GO:0045662;negative regulation of myoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;6.518977089658987;0.0038363580074348307;0.6565011041187423;[TGFB1, DLL1]
GO:0045780;positive regulation of bone resorption;7.0;1.0;0.8509193652572005;9.628524252492122;82.90338698468558;6.943860283624253;0.002774701754173115;0.7060287030842711;[TFRC, TNFSF11, TNFRSF11A, TMEM64]
GO:0050680;negative regulation of epithelial cell proliferation;6.0;0.7307253602413294;0.6884829927108091;8.690254613899192;65.19530579150691;4.989581884898423;0.0021820282128758306;0.5782877622231366;[PRL, PTPRK, BRCA2, MEF2C, TGFBR3, CEACAM1, SFN, TGFB1, CAV1]
GO:0120072;positive regulation of pyloric antrum smooth muscle contraction;10.0;1.0;0.9152410118609203;9.628524252492122;112.16807620771051;9.777073627680469;0.00375416456595737;0.9152410118609203;[KIT]
GO:0031100;animal organ regeneration;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;28.087648497102798;5.420364800990877;9.400683179555208E-4;0.5271977079954144;[CDKN1A, PCNA, C5AR1, TGFB1, ANXA3, SULF2, TGFBR3, EZH2]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[FGF5, TNFSF11, PDGFRB, GAB1, BTC, KIT, CHI3L1, HBEGF, ENG, CD19, TGFB1, TRAT1, EGF, PTK2, CD28, NOX4, TEK]
GO:0035265;organ growth;3.0;0.7671156992804218;0.5816781622303554;8.753055515138222;22.582921643529833;6.444869117505266;7.558300640989654E-4;0.5277112189764278;[PDGFRB, DLL1]
GO:1900272;negative regulation of long-term synaptic potentiation;9.0;1.0;0.896240625180289;9.628524252492122;54.24497338163739;7.57984905034425;0.0018155304417768478;0.7838744581139225;[CX3CR1]
GO:0045429;positive regulation of nitric oxide biosynthetic process;8.0;1.0;0.875;9.628524252492122;658.6394256443023;6.166155715036245;0.02204406883931546;0.6903374900225189;[PTGS2, KLRK1, AKT1, CD36, DNM2, PTX3, TLR4]
GO:0035025;positive regulation of Rho protein signal transduction;10.0;1.0;0.9152410118609203;9.628524252492122;339.6245583269611;6.481236761676141;0.01136692832494487;0.7466917612613706;[PDGFRB, F2R, GPR18, F2RL3]
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;4.629579150867016;0.008002824611389124;0.6117568930727868;[AKT1, TNFSF11, F2R, NDFIP2, PLK2, TNFRSF10B, CCDC22, FASLG, NUP62, CD36, LTF, FLNA, CD4, LTBR]
GO:0006024;glycosaminoglycan biosynthetic process;6.0;0.7586651285174919;0.7024528768488905;9.158520623246385;237.49504005673018;5.16195311083921;0.007948745259039342;0.5871028347338303;[SDC2, NDST3, ST3GAL6, PDGFRB, OGN, SDC1, CSPG4]
GO:0045663;positive regulation of myoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.26328322821418;6.7325511899570465;0.00382428925936973;0.6674232935401965;[MEF2C, TNFSF14]
GO:0045664;regulation of neuron differentiation;7.0;0.5064924996362321;0.6041656150753165;7.722354432086322;62.256296269576055;3.3619766685088743;0.0020836622091136505;0.5228510084326481;[CYFIP1, CPNE5, EDNRB, AKT1, MEF2C, EPHA3, SDC2, LYN, JAG1, BCL11B, PLK2, PTK2, EZH2, ITM2C, ROBO2, NRP1, SCARB2, PLXND1, TNR, SYT2, BCL6, TCF4, LRRK2, DCC, DNM2, NLGN1, LRP1, DLL1, CNR1, S1PR5, LINGO1, SEMA4B]
GO:0038091;positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;112.44183520208205;8.67846133901236;0.0037633270331318856;0.8590579283277371;[PDGFRB]
GO:0060389;pathway-restricted SMAD protein phosphorylation;8.0;1.0;0.875;9.628524252492122;180.75330000196035;7.212124270218933;0.006049650283656873;0.7438283705770736;[TGFBR3, TGFB1]
GO:0038093;Fc receptor signaling pathway;7.0;0.8436909121759173;0.7727648213451592;9.474373572664863;77.78262967477835;4.556717802602145;0.0026033146153928975;0.5839501255913225;[CYFIP1, IGHG1, FCGRT, GRAP2, CLEC4D, BTK, IGLV1-44, LYN, PTK2, IGKV3-20, LAT, CD3G, FCGR3A, FCER1A, LAT2, KIT, IGKC, FCGR1B, FCGR2A, FCGR2B]
GO:0044339;canonical Wnt signaling pathway involved in osteoblast differentiation;9.0;1.0;0.896240625180289;9.628524252492122;34.305501416841174;8.67846133901236;0.0011481742594748403;0.8400575416471059;[TMEM64]
GO:0002223;stimulatory C-type lectin receptor signaling pathway;11.0;1.0;0.9324289523296623;9.628524252492122;628.1099736002739;5.618190544320798;0.02102227555412486;0.7197434780388068;[ICAM2, KLRK1, MUC15, LYN, CLEC4D]
GO:0045668;negative regulation of osteoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.56398573135455;170.3268387162597;6.015873511986907;0.0057006860076304205;0.6307723637598831;[TMEM64]
GO:0097067;cellular response to thyroid hormone stimulus;6.0;0.8933024483968273;0.7697715367885581;9.485423408851448;110.48347060425422;7.004484905440688;0.003697782332456301;0.6813299963962409;[GHSR, KIT, GAS2L1, CTSS]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[IL5RA, FGF5, TNFSF11, PDGFRB, MEF2C, MAP2K2, BTC, CSF2RB, IQGAP3, RASGRP4, TGFB1, PTK2, LAT, LRRK2, SPTAN1, MAP4K1, DUSP6, KIT, HBEGF, NCAM1, EGF, IL2RB, TEK]
GO:0046085;adenosine metabolic process;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;443.46863639021404;7.474488534686424;0.01484249616411921;0.7784863164434164;[NT5E, ACPP, PTGDR]
GO:0045672;positive regulation of osteoclast differentiation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;840.7838216260375;6.599019797332524;0.0281402778535103;0.7337148045016781;[CCR1, TMEM64, TNFSF11]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, FPR1, FLRT2, HLA-DQA1, HLA-DRB4, CDKN1A, LRRC4, HLA-DPA1, FCER2, HLA-DQB1, LRRC19, PTAFR, PTGS2, ALOX5, IL12RB2, HLA-DPB1, CSF3R, F13A1, IL5RA, PYCARD, IGHG1, IL13RA2, IFNA14, IFNA16, IFNA10, TNFRSF11A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, TNFRSF10B, BCL6, LCN2, HLA-DRA, CIITA, ITGAM, FASLG, TNFRSF1B, CX3CR1, FCGR1B, IL2RB, TNFSF11, ACSL1, IL1R1, IL1R2, CCR10, CCR1, EGR1, TNFSF14, TNFSF12, SDC1, IFNA5, IFNA4, IFNA7, TNFRSF13B, IFNA2, IFNA8, CCR9, CCR6, CD36, CCR2, IL17RB, CEACAM1, KIT, RHOU, CXCR5, CXCR4, CXCR1, CXCR2, IL18R1, IL18RAP, CCRL2, IL6R, PRTN3, CSF2RB, TGFB1, CXCL1, CXCL2, GHR, LRRTM4, MMP9, SAMHD1, NCAM1, CD4, LTBR]
GO:0048388;endosomal lumen acidification;12.0;1.0;0.9481203125901445;9.628524252492122;182.53781204849716;8.67846133901236;0.006109376295897887;0.8919372290569614;[FASLG]
GO:0048146;positive regulation of fibroblast proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.74573076450893;5.825829909099042;0.0021335122412550348;0.6210535250702663;[CDKN1A, MYB, PDGFC, PDGFRB, TGFB1, CDC6, BTC]
GO:0043252;sodium-independent organic anion transport;7.0;1.0;0.8509193652572005;9.628524252492122;31.887457555831563;6.444869117505266;0.0010672445075450394;0.6805102716434839;[SLCO2B1, SLCO4C1]
GO:2000379;positive regulation of reactive oxygen species metabolic process;6.0;0.7763722522362496;0.7113064387082693;9.253830803050711;112.71770282919289;5.299736813202263;0.0037725600743465397;0.5941490996802742;[CDKN1A, PID1, ITGAM, AKT1, CD36, CD177, PDGFRB, DNM2, AGTR1, TLR4, FPR2, PTGS2, GNAI2, KLRK1, TGFB1, NOX4, PTX3]
GO:0060374;mast cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;47.07409398820286;8.67846133901236;0.0015755275618510598;0.7669372290569613;[KIT]
GO:0034162;toll-like receptor 9 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;7.004484905440688;0.013811191226989502;0.8063299963962409;[UNC93B1, TLR8, TLR7, HAVCR2]
GO:2001240;negative regulation of extrinsic apoptotic signaling pathway in absence of ligand;10.0;1.0;0.9152410118609203;9.628524252492122;570.2036429558796;6.221725566191056;0.019084202779771145;0.7334203466557586;[CX3CR1, AKT1]
GO:1903672;positive regulation of sprouting angiogenesis;8.0;0.8653626801206646;0.8076813400603323;9.446202695698167;183.7504864323888;6.139487467954083;0.00614996341619065;0.6889736746265369;[GHSR, NRP1, PLK2, PTGS2, DLL1, AGTR1]
GO:1904646;cellular response to amyloid-beta;7.0;1.0;0.8509193652572005;9.628524252492122;273.93391051768003;6.518977089658987;0.009168321460513012;0.6843001567857983;[LRP1, FPR2, ADRB2, GRM5, CD36, FCGR2B, TLR4]
GO:0008333;endosome to lysosome transport;6.0;0.8436909121759173;0.7449657686781032;9.36615998802463;62.67584315854233;5.769740442447999;0.0020977040659196657;0.618185107137305;[ADRB2, SORT1]
GO:0003323;type B pancreatic cell development;7.0;1.0;0.8509193652572005;9.628524252492122;37.346163459204256;7.379178354882098;0.001249942481614558;0.728290889492758;[DLL1]
GO:0030238;male sex determination;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.564882071422225;7.138016298065211;7.217571957966554E-4;0.6150384854347593;[PTGDR]
GO:0071260;cellular response to mechanical stimulus;5.0;1.0;0.7902410118609202;9.628524252492122;56.1235610070294;5.420364800990877;0.00187840507897962;0.5674387198563348;[CHEK1, AKT1, TLR8, TLR7, TLR5, TLR4, ENG, PTGS2, TGFB1, TNFSF14, TNFRSF10B, LTBR]
GO:0097755;positive regulation of blood vessel diameter;7.0;0.7508913569872202;0.7263650437508107;9.0689084645567;39.67967046252893;5.845247994956144;0.0013280428609958766;0.6498456195510879;[DOCK5, PTAFR, ADRB2, EDNRB, PTGDR]
GO:0060939;epicardium-derived cardiac fibroblast cell development;6.0;1.0;0.8231203125901445;9.628524252492122;34.925795330556404;9.777073627680469;0.00116893493853861;0.8231203125901445;[TGFBR3]
GO:0032411;positive regulation of transporter activity;6.0;0.6347111282356054;0.6404758767079473;8.242229891372231;47.08415081846268;5.223196736079928;0.0015758641549092965;0.5902348365767605;[KCNE3, PTAFR, ADRB2, CTSS, DRD4, ACTN4, ATP1B2, ATP1B1, SYNGR3, DNM2, SGK1]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[CSF3R, CXCL16, VPREB3, LGALS3, VPREB1, EDNRB, C3AR1, TNFSF11, IL6R, SLC16A3, CD177, CXADR, ATP1B2, ATP1B1, PRTN3, S100A8, GYPA, SDC2, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, CORO1A, NUP85, IGLV1-44, IGHA1, ELANE, LYN, CCR1, TGFB1, GPR15, CAV1, TNFRSF10B, AZU1, DEFA1, SELE, SDC1, IGKV3-20, IGHM, ITGAM, CXCL1, SLC7A11, CXCL2, TREM1, OLR1, FFAR2, CCR6, CCR2, MMP9, SLC7A5, CEACAM1, SLC7A7, SLC7A8, CEACAM6, KIT, PECAM1, CX3CR1, CXCR5, CXCR4, IGKC, CXCR1, EPCAM, CXCR2, CD58, JAM2, JAM3, CD2, NLRP12, TEK]
GO:0007171;activation of transmembrane receptor protein tyrosine kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1143.6879814690685;7.212124270218933;0.03827820748741112;0.8169486831672182;[EGF, PDGFC, ADRB2]
GO:0045608;negative regulation of inner ear auditory receptor cell differentiation;11.0;0.9326813400603323;0.8987696223598284;9.60185600540996;1107.5091840940604;8.67846133901236;0.03706733569807334;0.8762458687964789;[DLL1]
GO:1904251;regulation of bile acid metabolic process;7.0;0.8259837884571596;0.7639112594857803;9.446202695698167;58.70275173925325;7.292166977892469;0.0019647282716661932;0.7238411236270654;[KIT]
GO:0038110;interleukin-2-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.379178354882098;0.00101047745553359;0.728290889492758;[IL2RB]
GO:0002281;macrophage activation involved in immune response;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;81.79914540449643;7.379178354882098;0.0027377437822370863;0.7004918368257019;[CX3CR1, SUCNR1, HAVCR2]
GO:0007179;transforming growth factor beta receptor signaling pathway;8.0;0.7586651285174919;0.754332564258746;9.05316010758856;29.903672154863813;5.2552850506314295;0.0010008489954655988;0.6437555218850388;[PTPRK, CDH5, TGFBR3, ADAM9, TGFB1, PTK2, ZYX]
GO:0002282;microglial cell activation involved in immune response;7.0;1.0;0.8509193652572005;9.628524252492122;112.99588726958953;9.083926447120524;0.003781870657216873;0.8154717862087246;[CX3CR1]
GO:0006520;cellular amino acid metabolic process;6.0;0.406884124246779;0.526562374713534;6.526182243879872;77.81072980309767;4.002522082136061;0.0026042551013992716;0.5278094780068945;[KMO, SLC1A3, SLC6A6, HAL, NOX4, GHR, ARG1, SLC7A5, SLC7A7, SLC7A8]
GO:0045600;positive regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.26328322821418;5.71663061713405;0.00382428925936973;0.6154690682008903;[PTGS2, AKT1, TMEM64, KLF5]
GO:0045840;positive regulation of mitotic nuclear division;8.0;0.7140352122741334;0.7320176061370667;9.138976027173417;276.06341799230654;5.75172193694532;0.009239594159256459;0.6691433273378073;[TGFA, NUP62, SH2B1, PDGFRB, RANBP1, TGFB1, EGF, BTC, CD28]
GO:0043303;mast cell degranulation;9.0;1.0;0.896240625180289;9.628524252492122;196.3355458728175;7.138016298065211;0.006571174029843636;0.7612791106150483;[LAT2, KIT, LAT]
GO:0003376;sphingosine-1-phosphate signaling pathway;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;50.14720301582843;7.292166977892469;0.001678381755387122;0.6960420709600095;[SPNS1, S1PR3, GPR6, S1PR5]
GO:0050873;brown fat cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;21.75937296335754;6.444869117505266;7.282666309192915E-4;0.6198319182472036;[LAMB3, ADRB2, PTGS2, LRG1]
GO:0050870;positive regulation of T cell activation;8.0;0.6260725219892441;0.688036260994622;8.781226392104918;216.0655637178415;4.493869898942481;0.007231519971253338;0.6048167156182404;[CD83, TFRC, PYCARD, GRAP2, MYB, AKT1, TNFSF11, IL6R, ICOSLG, CD274, BLM, HHLA2, CORO1A, KLRK1, BTLA, NLRP3, LYN, TGFB1, EGR3, TNFSF14, CAV1, VNN1, BCL6, CD28, CD24, CD3E, SIRPB1, CCR2, HLA-DPA1, HAVCR2, PDCD1LG2, LILRB1, LILRB2, CD4, HLA-DPB1]
GO:0030509;BMP signaling pathway;11.0;0.7090535922965819;0.7869557484779532;9.133828010656014;282.55034729266697;5.202362649177086;0.009456705845082177;0.6984780201431826;[TMEM100, EGR1, TGFB1, RUNX2, TGFBR3, ENG]
GO:0045055;regulated exocytosis;7.0;0.6873818243518346;0.6946102774331178;8.567652291806858;38.46917486033492;3.2638435167681625;0.0012875286625657566;0.5178324744889699;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, LYN, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, NFAM1, ANXA5, F5, SERPINB10, PTAFR, ALOX5, FLNA, GSN, LRG1, SLCO4C1, SIGLEC5, HP, F13A1, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, GPR84, CORO1A, ATP8B4, DEFA4, DEFA1, LCN2, LAT, ITGAM, FCAR, FCGR3B, CR1, TNFRSF1B, PECAM1, BPI, ACPP, FCGR2A, P2RX1, FOLR3, LGALS3, ANPEP, ACTN1, SLC11A1, ACTN4, CHIT1, SLPI, CRISPLD2, TLN1, STXBP2, MGST1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSG, CD36, SPTAN1, CAMP, CD33, MME, RHOG, LAT2, CEACAM1, CEACAM6, KIT, TLR2, LILRA3, CXCR1, CXCR2, CD58, LHFPL2, LILRB2, LILRB3, QPCT, CD97, CHRNB4, CD93, OSCAR, DOK3, PRTN3, C5AR1, MGAM, TGFB1, SYT2, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, SYNGR3, MMP9, CHI3L1, LTF, CLEC12A, RETN, EGF, CD9, S100P, PTX3]
GO:0031398;positive regulation of protein ubiquitination;10.0;0.7508913569872202;0.7906866903545304;9.372590878354922;528.4459358446122;5.113634533568402;0.01768660990225356;0.6767525197159333;[LRRK2, SKP2, ADRB2, NDFIP2, WFS1, CAV1]
GO:0019722;calcium-mediated signaling;7.0;0.7192862368539868;0.710562483684194;8.712233520617966;27.814661162170232;4.835431205071165;9.309316775279788E-4;0.598203541955087;[MCTP1, LRRK2, SLC8A1, GRM5, EDNRB, CCRL2, CCR9, TNFSF11, CCR6, CCR2, AVPR1A, ATP1B1, LAT2, BTK, AGTR1, CX3CR1, CXCR5, CXCR4, FPR2, CXCR1, CXCR2, CCR10, CCR1, AZU1, SELE, LAT]
GO:0038109;Kit signaling pathway;8.0;1.0;0.875;9.628524252492122;61.193638670852046;9.083926447120524;0.002048096015614107;0.839552420951524;[KIT]
GO:0030501;positive regulation of bone mineralization;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;171.85898464291293;6.221725566191056;0.005751965552953692;0.6690987000520388;[MEF2C, TGFB1, ADRB2, SLC8A1, LTF]
GO:0007181;transforming growth factor beta receptor complex assembly;6.0;1.0;0.8231203125901445;9.628524252492122;44.51706700895919;8.67846133901236;0.0014899461700306506;0.7669372290569613;[TGFBR3]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[EDNRB, GPR171, C3AR1, AKT1, PROK2, PTGDR, TAS2R10, TAS2R13, TAAR2, TRHR, ADCY9, AGTR1, FPR1, FPR3, FPR2, CCR10, CCR1, ABCA1, GPR15, FZD5, OR2J2, AZU1, NMBR, MARCO, PNOC, GPR18, GPR19, GPR25, GABRB1, CD3E, CCR9, FFAR2, CCR6, CCR2, GPR37, RHOG, GPBAR1, TACR3, AGTRAP, PTH2R, AVPR1A, SORCS3, MC3R, PTGER2, PTAFR, CXCR5, CXCR4, GNAI1, GNAI2, FGD4, CXCR1, CXCR2, FLNA, GABRE, GPR157, P2RY13, GABBR1, SORT1, GABRA5, P2RY14, GPR6, RAMP1, LGR4, F2RL3, CHRM2, CHRM1, CELSR1, CXCL16, RGS1, CCRL2, PDGFRB, CD97, GHSR, LHCGR, F2R, NPY1R, DGKZ, SPNS1, SUCNR1, CALCRL, GPR87, C5AR1, GPR85, GPR84, ADRB2, GPR82, HRH4, DRD4, HTR1E, CAV1, GPR98, GNB2, TAS2R7, OR1G1, CXCL1, CXCL2, GRM5, PTGIR, GLP2R, CX3CR1, LRP1, OR1E1, P2RY6, CNR1, P2RY2, OR2W1, S1PR3, OR12D3, S1PR5, TSHR, OR11A1]
GO:0031274;positive regulation of pseudopodium assembly;9.0;0.9326813400603323;0.8625812952104552;9.571365838652174;200.71212349518538;7.212124270218933;0.006717654144200148;0.7650689957573628;[KIT]
GO:0043552;positive regulation of phosphatidylinositol 3-kinase activity;11.0;0.9326813400603323;0.8987696223598284;9.597752593825367;732.6859750532908;6.375876246018314;0.024522340210466318;0.7584915600596062;[LYN, PDGFRB, TGFB1, FPR2, PTK2, KIT, TEK]
GO:0060437;lung growth;4.0;1.0;0.75;9.628524252492122;24.192359555962447;8.67846133901236;8.096965026280019E-4;0.6938169164668168;[PDGFRB]
GO:0060317;cardiac epithelial to mesenchymal transition;6.0;0.7980440201809971;0.722142322680643;9.0094850440859;24.75510523691153;6.481236761676141;8.285310941311355E-4;0.6545710619905948;[TMEM100, TGFBR3, ENG]
GO:0002052;positive regulation of neuroblast proliferation;8.0;1.0;0.875;9.628524252492122;500.99868276789744;6.781341354126479;0.016767975042699966;0.7217981122146513;[CX3CR1]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, NFAM1, SERPINB10, PTAFR, ALOX5, GSN, LRG1, SLCO4C1, SIGLEC5, HP, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, GPR84, ATP8B4, DEFA4, DEFA1, LCN2, ITGAM, FCAR, FCGR3B, CR1, TNFRSF1B, PECAM1, BPI, ACPP, FCGR2A, P2RX1, FOLR3, LGALS3, ANPEP, SLC11A1, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSG, CD36, SPTAN1, CAMP, CD33, MME, RHOG, CEACAM1, CEACAM6, TLR2, LILRA3, CXCR1, CXCR2, CD58, LILRB2, LILRB3, QPCT, CD97, CHRNB4, CD93, OSCAR, DOK3, PRTN3, C5AR1, MGAM, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, S100P, PTX3]
GO:0060318;definitive erythrocyte differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;24.061958056348765;9.083926447120524;8.053320817896622E-4;0.7876727335416686;[TGFBR3]
GO:0007189;adenylate cyclase-activating G-protein coupled receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.249034630787218;56.871035456649615;5.192106149009898;0.0019034223761250782;0.6617651750982834;[CALCRL, PTGER2, ADRB2, GNAI2, PTGDR, ABCA1, LHCGR, PTGIR, TSHR, MC3R, ADCY9, RAMP1, LGR4]
GO:0042102;positive regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;564.8543510249671;5.212725436212633;0.018905166792893686;0.6628196464047262;[TFRC, CD3E, PYCARD, IL6R, ICOSLG, CCR2, HLA-DPA1, HAVCR2, PDCD1LG2, CD274, BLM, HHLA2, CORO1A, LILRB2, CD4, CD28, HLA-DPB1, CD24]
GO:0061885;positive regulation of mini excitatory postsynaptic potential;9.0;1.0;0.896240625180289;9.628524252492122;500.93526069116905;9.777073627680469;0.01676585236286803;0.896240625180289;[ADRB2]
GO:0006897;endocytosis;5.0;0.6324783794010864;0.6064802015614634;8.088079211544972;26.35802846831835;3.582668236575797;8.821794921490709E-4;0.47345883209051776;[TFRC, SLC11A1, FPR2, IGHA1, ELANE, MSR1, MARCO, DENND1B, ASGR1, ASGR2, CD36, ANXA3, CEACAM1, RHOU, CD302, IGKC, CXCR1, CXCR2, SORT1, LILRB1, SIGLEC1, RAMP1, SCARB2, NCF4, HP, CXCL16, PYCARD, AP2M1, CD93, TSC2, PRTN3, CALCRL, PLD4, ADRB2, CORO1A, IGLV1-44, CD163, SYT2, CAV1, LRP1B, MARCH3, IGKV3-20, LRP12, LRRK2, GHR, DNM2, PECAM1, COLEC12, NLGN1, LRP1, CEBPE, DLL1, FCGR1B, ATP9A, NLGN4Y, CD9, FCGR2B]
GO:0006898;receptor-mediated endocytosis;6.0;0.6799073451904818;0.6630739851853854;8.48339194818912;28.437470009997963;4.178651668682095;9.517765291732001E-4;0.536816753253722;[SCARB2, TFRC, HP, CXCL16, AP2M1, CALCRL, FPR2, ADRB2, IGLV1-44, IGHA1, MSR1, CD163, CAV1, LRP1B, MARCO, IGKV3-20, LRP12, ASGR1, ASGR2, CD36, DNM2, CEACAM1, COLEC12, LRP1, DLL1, IGKC, CXCR1, CXCR2, FCGR1B, LILRB1, CD9, FCGR2B, RAMP1]
GO:2000969;positive regulation of AMPA receptor activity;10.0;1.0;0.9152410118609203;9.628524252492122;1126.3301560195273;8.16763571524637;0.03769725669064368;0.8329342821725234;[ADRB2]
GO:0045063;T-helper 1 cell differentiation;11.0;1.0;0.9324289523296623;9.628524252492122;473.70362526189734;8.16763571524637;0.01585443403193107;0.8501222226412654;[IL18R1]
GO:0071560;cellular response to transforming growth factor beta stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;5.788089581116195;0.003262744749111514;0.6191234829421188;[CX3CR1, MEF2C, TGFB1, ARG1, CAV1, NOX4]
GO:0033209;tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;30.19135422731818;5.395046993006588;0.00101047745553359;0.6268223193749;[TNFRSF13B, PYCARD, TNFSF11, TNFRSF1B, TNFRSF11A, TNFRSF17, TNFSF14, TNFSF12, TNFRSF10C, TNFRSF10B, LTBR]
GO:0001756;somitogenesis;5.0;1.0;0.7902410118609202;9.628524252492122;43.80328827915336;5.845247994956144;0.0014660566383032007;0.5891672661548076;[DLL1]
GO:0001757;somite specification;4.0;1.0;0.75;9.628524252492122;23.491373237041078;8.16763571524637;7.862351213804327E-4;0.6676932703116032;[DLL1]
GO:2000726;negative regulation of cardiac muscle cell differentiation;9.0;0.8436909121759173;0.8180860812682478;9.4949928598676;669.6541776470041;7.292166977892469;0.022412722676212672;0.769162383550154;[DLL1]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[BRCA2, CTGF, PDGFRB, GHSR, DUSP1, TACR3, PCNA, ABCB4, PTGS2, RBBP8, TGFB1, GH1, CD4, EZH2]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CTGF, CXCL16, FGF5, VSTM1, TNFSF11, MEF2C, IFNA14, IFNA16, BTC, IFNA10, TGFA, ADRB2, PDGFC, IFNA21, TGFB1, JAG1, TNFSF14, TNFSF12, INHBA, GH1, PNOC, OGN, IFNA5, IFNA4, NRP1, IFNA7, IFNA2, CXCL1, FASLG, PRL, IFNA8, CXCL2, HBEGF, NLGN1, CLEC12B, RETN, GPNMB, EGF, CMTM2, FCGR2B]
GO:0032354;response to follicle-stimulating hormone;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;26.60980005211952;6.943860283624253;8.906060604791816E-4;0.6782296504172152;[TGFBR3, GHSR, POR, INHBA]
GO:0035744;T-helper 1 cell cytokine production;8.0;1.0;0.875;9.628524252492122;53.326986718937256;8.390779266560578;0.0017848062543106336;0.8041048419030481;[IL18RAP]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[CYFIP1, PLXND1, VRK1, CORO1A, PTK2, RHOG, ARAP3, KIT, RHOU, FGD4, PDPN]
GO:0046718;viral entry into host cell;7.0;0.7671156992804218;0.7344772148974115;8.935377071932177;28.374411874040543;5.346256828837156;9.496660301113433E-4;0.6243271881103005;[SCARB2, TFRC, ANPEP, CLEC5A, ITGB6, CR2, CR1, CXADR, GYPA, NCAM1, GPR15]
GO:0042119;neutrophil activation;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;20.951462914457938;3.578594911188161;7.012266086544604E-4;0.5061298227699893;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, NFAM1, SERPINB10, PTAFR, ALOX5, GSN, LRG1, SLCO4C1, SIGLEC5, HP, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, GPR84, ATP8B4, DEFA4, DEFA1, LCN2, ITGAM, FCAR, FCGR3B, CR1, TNFRSF1B, PECAM1, BPI, ACPP, FCGR2A, P2RX1, FOLR3, LGALS3, ANPEP, SLC11A1, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSG, CD36, SPTAN1, CAMP, CD33, MME, RHOG, CEACAM1, CEACAM6, TLR2, LILRA3, CXCR1, CXCR2, CD58, LILRB2, LILRB3, QPCT, IL18RAP, CD97, CHRNB4, CD93, OSCAR, DOK3, PRTN3, C5AR1, MGAM, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, S100P, PTX3]
GO:0036035;osteoclast development;5.0;1.0;0.7902410118609202;9.628524252492122;66.38585475831493;7.9853141584524145;0.0022218748153703875;0.6986103492792611;[TNFSF11]
GO:0014002;astrocyte development;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;34.09911675737102;6.832634648514029;0.001141266750656509;0.639662265535933;[PLP1, TSPAN2, DLL1, S100A8]
GO:0036152;phosphatidylethanolamine acyl-chain remodeling;8.0;1.0;0.875;9.628524252492122;185.56639978848355;6.518977089658987;0.0062107404020032226;0.7083807915285978;[RARRES3, MBOAT2]
GO:0045742;positive regulation of epidermal growth factor receptor signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;233.1839134473908;6.280566066213989;0.0078044557311868065;0.6961884407023742;[EGF, TGFA, FASLG, MMP9, NUP62, AKT1]
GO:0045747;positive regulation of Notch signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;187.6437959822434;5.926926025970411;0.006280268983073171;0.6540226378555745;[DLL1, TSPAN5, JAG1, KIT]
GO:0045986;negative regulation of smooth muscle contraction;8.0;0.7508913569872202;0.7504456784936101;8.98189708756707;66.40311154199819;7.138016298065211;0.002222452384390169;0.7400384854347593;[DOCK5, CALCRL, ADRB2, PTGS2]
GO:0002025;norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure;9.0;1.0;0.896240625180289;9.628524252492122;55.18689913553991;8.67846133901236;0.0018470558490818227;0.8400575416471059;[ADRB2]
GO:0035855;megakaryocyte development;5.0;1.0;0.7902410118609202;9.628524252492122;66.38585475831493;7.069023426578259;0.0022218748153703875;0.6517511986393402;[KIT]
GO:0033674;positive regulation of kinase activity;9.0;0.6073376606709605;0.6999094555157693;8.620883742029738;265.89784403492143;3.4106031799490317;0.008899361547325376;0.5706590304121504;[, CCNH, TCL1A, AKT1, PROK2, TNFSF11, ACSL1, SLC11A1, EPHA3, FPR1, TGFA, FPR2, IQGAP3, PRKAR2B, PDGFC, ELANE, LYN, EGR1, ACE, FZD5, CDC6, AZU1, PTK2, NOX4, CD24, EZH2, CDKN1A, MAP4K1, DUSP6, KIT, TLR4, CXCR4, PKN1, IL6R, PDGFRB, MAP2K2, F2R, ADAM9, C5AR1, TNFRSF11A, ADRB2, STAP1, DRD4, TGFB1, TNFRSF10B, GH1, CSPG4, LAT, LRRK2, GHR, GRM5, PSRC1, CHI3L1, LTF, EGF, TIE1, CD4, TEK]
GO:0014911;positive regulation of smooth muscle cell migration;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;201.77833622021802;6.280566066213989;0.0067533393245778365;0.6961884407023742;[PDGFRB, DOCK5, NRP1, P2RY6, NOX4]
GO:0050776;regulation of immune response;4.0;0.37937792944451876;0.4396889647222594;5.635843344046521;22.446924158408432;2.846578861728843;7.512783506617425E-4;0.39557417536826767;[, CYFIP1, TFRC, SLA2, MYB, C3AR1, UBASH3A, MEF2C, CXADR, HHLA2, FPR1, FPR3, FPR2, KLRK1, IGHA1, HLA-DQA1, ELANE, LYN, HLA-DRB4, FZD5, KIR2DS1, KIR2DS2, DENND1B, SIGLEC9, HLA-DPA1, HAVCR2, ARG1, FCRL3, NFAM1, PAWR, PAX5, MMP12, FCER2, TLR10, HLA-DQB1, PTAFR, UNG, NR1H2, KIR3DL1, HLA-DPB1, PKN1, CLC, LGR4, PYCARD, IGHG1, FCGRT, GRAP2, IL13RA2, CD177, LAG3, CD180, MSH6, CLEC4D, MSH2, S100A8, BLK, CD274, LY96, IGLV1-44, BMX, BCL6, HLA-DRA, LAT, ITGAM, TREM2, TREM1, FCGR3A, CR2, CR1, PVRIG, UNC93B1, NLRC4, FCGR1B, FCGR2A, FCGR2B, ICAM2, LGALS3, ICOSLG, SLC11A1, BTK, STXBP2, CD1E, CD1B, CD1A, CD79B, CD79A, CD19, SLAMF7, SH2D1A, PTK2, MARCO, CD28, CD24, CD200, IGHM, IFNA2, CD3G, CD3E, CTSS, FCER1A, FFAR2, CTSG, MUC15, CD36, CD33, CCR2, LAT2, TLR1, NCR1, CEACAM1, KIT, IGHD, TLR8, TLR7, TLR5, TLR4, TLR2, IGKC, LILRB1, LILRB2, MLH1, IL18RAP, IL6R, OSCAR, KLRF1, CD300C, C5AR1, KIR2DL1, KIR2DL2, KIR2DL3, STAP1, NLRP3, TGFB1, CAV1, IGKV3-20, HMGB2, LTF, COLEC12, CLEC12B, SAMHD1, CNR1, TRAT1, CD4]
GO:0045638;negative regulation of myeloid cell differentiation;7.0;0.7307253602413294;0.7162820453778652;9.186691500213083;279.0827475916144;5.4730085344763;0.00934064840372507;0.6308092762312435;[HOXA9, GPR171, CEACAM1, TLR4, LTF, DLL1, LYN, LILRB1, INHBA, LILRB3, MEIS2]
GO:0060333;interferon-gamma-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.514393750639154;0.00101047745553359;0.6329257181104212;[CIITA, HLA-DPA1, HLA-DQB1, PTAFR, NCAM1, FCGR1B, HLA-DQA1, HLA-DRB4, HLA-DPB1, HLA-DRA]
GO:0007286;spermatid development;5.0;1.0;0.7902410118609202;9.628524252492122;72.7828096339012;5.370354380416217;0.0024359751381706407;0.5648811846224242;[JAM3, KIT]
GO:1903514;release of sequestered calcium ion into cytosol by endoplasmic reticulum;15.0;0.9326813400603323;0.9547019944812309;9.607904965289386;524.5434794588007;7.697632086000634;0.017555998199003178;0.8820185873056371;[FASLG]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[, SLA2, C3AR1, AKT1, MEF2C, HHLA2, FPR1, FPR3, FPR2, SLC30A10, KLRK1, PDGFC, LYN, ABCA1, JAG1, HLA-DRB4, VANGL1, SIGLEC9, LRRC4, HLA-DPA1, PTH2R, LRRC19, PTAFR, PTGS2, FLNA, IL12RB2, P2RY13, P2RY14, TMEM64, HLA-DPB1, LGR4, NCF4, F13A1, CTGF, AP2M1, LAG3, IFNA14, IFNA16, IFNA10, BLK, CD274, GPR87, TACSTD2, LY96, TNFRSF11A, CORO1A, FOXO1, TNFRSF17, IFNA21, GPR98, TNFRSF10C, TNFRSF10B, BMX, LCN2, HLA-DRA, CIITA, ITGAM, ITGB4, LRRK2, FASLG, HHEX, FCGR3A, ITGB6, TNFRSF1B, TSPAN33, FCGR1B, TSPAN13, FCGR2A, IL2RB, FCGR2B, ICAM2, TNFSF11, BTC, BTK, EPHA3, SDC2, TGFA, CD19, TSPAN5, TSPAN2, CCR1, EGR1, TNFSF14, TNFSF12, PTK2, CD28, SDC1, CD24, IGHM, NRP1, PTPRR, NRP2, TNFRSF13B, CD3G, PTPRK, CD3E, CCR9, FCER1A, CD37, CCR6, MUC15, CD36, CCR2, GAB1, LAT2, KIT, IGHD, GNAI2, IGKC, SORT1, IL18R1, CELSR1, CCRL2, IL6R, PDGFRB, CD97, GEM, OSCAR, CCNE1, PSEN2, KIR2DL1, RASGRP4, CRIM1, INHBA, GH1, IGKV3-20, SIRPB1, GHR, GRM5, NUP62, MMP9, SAMHD1, EGF, CD2, CD4, CD7, CD9, TEK, CDA, CYFIP1, STMN1, GPR171, FLRT2, IGHA1, HLA-DQA1, FZD5, CDK14, DENND1B, CDKN1A, ASGR2, NFAM1, AES, FCER2, HBEGF, ENG, HLA-DQB1, ALOX5, GPR157, G0S2, SULF2, ZYX, PLP1, CSF3R, PLXND1, IL5RA, FGF5, PYCARD, CDH5, IGHG1, CDH3, FCGRT, GRAP2, IL13RA2, TLE4, CLEC4D, ADAM9, CD151, CALCRL, IGLV1-44, BCL6, CSPG4, LAT, CR2, CR1, CX3CR1, P2RY6, P2RY2, SEMA4B, P2RX5, P2RX1, EDNRB, ICOSLG, ACSL1, IL1R1, IL1R2, RUNX2, TLN1, PFN1, APCDD1, CD79B, CD79A, CCR10, NMBR, MARCO, IFNA5, ROBO2, IFNA4, IFNA7, IFNA2, PRL, IFNA8, FFAR2, GP1BB, GPBAR1, PDCD1LG2, IL17RB, CEACAM1, RHOU, TLR4, TLR2, CXCR5, CXCR4, CXCR1, CXCR2, LILRB1, LILRB2, LILRB3, KRT19, IL18RAP, TSC2, KIF16B, KLRF1, PRTN3, C5AR1, CSF2RB, ADRB2, STAP1, TGFB1, NR4A2, CXCL1, CXCL2, TMEM100, LRRTM4, BLNK, DCC, GLP2R, TGFBR3, CLEC12B, DLL1, REPS2, S1PR3, NCAM1, TRAT1, TSHR, LTBR]
GO:0002032;desensitization of G-protein coupled receptor protein signaling pathway by arrestin;9.0;1.0;0.896240625180289;9.628524252492122;416.97188309209935;9.083926447120524;0.013955673676761097;0.8607930461318132;[ADRB2]
GO:0070371;ERK1 and ERK2 cascade;10.0;1.0;0.9152410118609203;9.628524252492122;233.3964595037646;6.481236761676141;0.007811569456414605;0.7466917612613706;[MAP2K2, EGF, IQGAP3, TNFSF11]
GO:0090090;negative regulation of canonical Wnt signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.283683766200392;236.99226377157444;4.932886541221878;0.00793191778924446;0.6272680471207706;[TLE4, AES, FOXO1, EGR1, CAV1, TMEM64]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[HMGB2, CXCL1, CXCL2, PYCARD, EDNRB, CTSG, CD36, HAVCR2, GHSR, MEF2C, ARG1, CD180, PDCD1LG2, TNFRSF1B, ADAM9, TLR4, CX3CR1, CD274, CEBPE, KLRK1, STAP1, NLRP3, ABCA1, NR1H2, DEFA4, LILRB1, DEFA1, LILRB2]
GO:0014807;regulation of somitogenesis;6.0;0.811012628672052;0.7286266269261705;9.223059144383958;45.909253739235254;7.57984905034425;0.0015365414070062774;0.710754145523778;[DLL1]
GO:0042130;negative regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;581.9323154417883;5.734022359845919;0.01947675089275457;0.6894787953221185;[CD274, GPNMB, HAVCR2, TGFB1, ARG1, PAWR, LILRB1, PDCD1LG2, LILRB2]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[, SLA2, LGALS3, RNASE6, RNASE3, SLPI, BTK, LY9, KLRK1, SLAMF7, IGHA1, LYN, KIR2DS1, KIR2DS2, SH2D1A, KIR2DS4, KIR2DS5, PTK2, MARCO, VNN1, IFNA5, IFNA4, IGHM, IFNA7, IFNA2, IFNA8, CAMP, HAVCR2, ARG1, TLR1, IGHD, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2, LILRA5, IGKC, KIR3DL1, LGR4, PYCARD, IGHG1, GRAP2, CLEC5A, CD177, IFNA14, IFNA16, CD180, CLEC4D, S100A8, IFNA10, BLK, LY96, CORO1A, NLRP3, IFNA21, TGFB1, DEFA4, DEFA1, BMX, LCN2, ITGAM, CRISP3, HMGB2, TREM2, TREM1, SIRPB1, CR2, CR1, LTF, COLEC12, UNC93B1, HIST1H2BK, NLRC4, PTX3]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[CTGF, PYCARD, TNFSF11, PDGFRB, F2R, EPHA3, C5AR1, FPR2, TNFRSF11A, SLC30A10, PDGFC, CCR1, TGFB1, MARCO, NOX4, NRP1, TREM2, CD36, HAVCR2, KIT, CHI3L1, GNAI2, GPNMB, TIE1, CD4, TEK]
GO:0002826;negative regulation of T-helper 1 type immune response;8.0;0.8933024483968273;0.8216512241984136;9.503361109538115;172.20109340032639;7.8311634786251565;0.005763415625186428;0.7754860644832351;[HAVCR2]
GO:0035723;interleukin-15-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.212124270218933;0.00101047745553359;0.7197477358342742;[CD4, IL2RB]
GO:0030032;lamellipodium assembly;6.0;0.8933024483968273;0.7697715367885581;9.533214072687796;78.21732158183345;6.311337724880743;0.002617863362324714;0.6458824173477649;[CYFIP1, NUP85, KIT, SH2B1]
GO:0071345;cellular response to cytokine stimulus;5.0;0.6729672293956388;0.6267246265587396;8.214830917184116;61.59823360834823;3.805811787890007;0.0020616374440603005;0.48487040368196277;[PID1, TFRC, TCL1A, AKT1, TNFSF11, BTK, PADI2, STXBP2, ST3GAL6, EGR1, HLA-DPA1, MME, ARG1, TLR4, TLR2, CXCR4, CD58, GSN, NLRP12, ZYX, IL18R1, PYCARD, TLE4, KMO, KIF16B, CSF2RB, CORO1A, CHI3L1, MCM2, CD4, KLF5]
GO:2000502;negative regulation of natural killer cell chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;1002.759017369874;9.083926447120524;0.03356144188684441;0.8969813732811862;[KLRK1]
GO:0035722;interleukin-12-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.948432231191374;0.00101047745553359;0.6551224661907153;[IL12RB2]
GO:0014068;positive regulation of phosphatidylinositol 3-kinase signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;5.602686357784832;0.007979625599047746;0.6615216408886768;[PDGFC, PDGFRB, F2R, PTK2, GH1, KIT, CD28, TEK]
GO:0034112;positive regulation of homotypic cell-cell adhesion;6.0;0.8653626801206646;0.7558016526504768;9.427853557029971;52.782758271627834;7.9853141584524145;0.001766591417952991;0.7314896500084853;[PDPN, TNFSF11]
GO:0045807;positive regulation of endocytosis;7.0;0.6873818243518346;0.6946102774331178;8.89763674394933;124.48668476360231;4.886724499458715;0.0041664573082951335;0.6008266834154484;[LRRK2, SIRPB1, PYCARD, CD36, SLC11A1, ACTN4, DNM2, NLGN1, CD151, LRP1, DLL1, STAP1, EGF, AZU1, SELE, PTX3, FCGR2B]
GO:0034351;negative regulation of glial cell apoptotic process;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;104.32654737607098;7.697632086000634;0.003491715652880169;0.7686572628545723;[DLL1]
GO:1901741;positive regulation of myoblast fusion;9.0;1.0;0.896240625180289;9.628524252492122;353.2013099653272;6.8867018697843045;0.011821329983997786;0.7484268790654467;[TNFSF14]
GO:0042531;positive regulation of tyrosine phosphorylation of STAT protein;11.0;1.0;0.9324289523296623;9.628524252492122;1230.2749798860389;5.618190544320798;0.04117619640118775;0.7197434780388068;[IFNA2, GHR, IL6R, LYN, GH1, KIT]
GO:0048633;positive regulation of skeletal muscle tissue growth;9.0;1.0;0.896240625180289;9.628524252492122;367.14841175535776;8.390779266560578;0.012288126929333416;0.8253454670833372;[DLL1]
GO:0008625;extrinsic apoptotic signaling pathway via death domain receptors;7.0;0.9326813400603323;0.8172600352873667;9.523163736834295;52.44533375847466;6.311337724880743;0.0017552981231601008;0.6736814700148209;[FASLG, SORT1, TNFRSF10B]
GO:0006687;glycosphingolipid metabolic process;7.0;0.6763753087927167;0.6891070196535589;9.040737587590003;147.45961877692685;5.734022359845919;0.004935340735422783;0.64415753539903;[KIT]
GO:0072070;loop of Henle development;8.0;0.9326813400603323;0.8413406700301662;9.533214072687796;58.05347923817328;8.390779266560578;0.001942997705362361;0.8041048419030481;[JAG1, DLL1]
GO:0032967;positive regulation of collagen biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;105.22247330055487;6.558197802812269;0.003521701487291661;0.6585068532133508;[PDGFRB, TGFB1, MYB, F2R, ENG, CTGF]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[SLC8A1, MYB, AKT1, ACTN4, ATP1B1, CLDN3, ABCB4, PSEN2, EGR1, TGFB1, CAV1, NR4A2, NOX4, CD24, KCND2, AGTRAP, TGFBR3, TLR2, CXCR4, PTGS2, TEK]
GO:0032729;positive regulation of interferon-gamma production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;5.6339389012889365;0.002183412136085803;0.6112402100070131;[CD3E, PYCARD, IL6R, CCR2, HLA-DPA1, HAVCR2, SLC11A1, TLR8, TLR7, TLR4, KLRK1, IL12RB2, FZD5, CD2, HLA-DPB1, IL18R1]
GO:0071656;negative regulation of granulocyte colony-stimulating factor production;7.0;1.0;0.8509193652572005;9.628524252492122;82.4613861827968;9.777073627680469;0.0027599083851087935;0.8509193652572005;[HAVCR2]
GO:0032722;positive regulation of chemokine production;6.0;0.7140352122741334;0.6801379187272112;8.734706376470026;66.68357405504983;5.8067817141283475;0.002231839212302133;0.6200793994936333;[PYCARD, FFAR2, IL6R, HAVCR2, EGR1, AZU1, TLR7, TLR4, TLR2]
GO:0032720;negative regulation of tumor necrosis factor production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.92712208559752;5.926926025970411;0.002875903446815721;0.6540226378555745;[ORM1, GPNMB, HAVCR2, GHSR, LILRB1, BPI, TLR4, GPR18]
GO:0050830;defense response to Gram-positive bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.334422371190153;0.0023911797157970473;0.6237219733958743;[SEH1L, HIST1H2BK, C5AR1, HMGB2, KLRK1, NLRP3, CD36, CAMP, HAVCR2, DEFA4, RNASE6, RNASE3, DEFA1, LYZ, TLR2]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[AKT1, MEF2C, AGTR1, FPR1, FPR2, IQGAP3, PRKAR2B, SFN, LYN, ABCA1, AZU1, ARHGAP6, DUSP1, DUSP6, PTAFR, PKN1, LGR4, CTGF, KCNH1, MSH6, MSH2, BLK, LY96, TNFRSF10B, BMX, CORO2A, LRRK2, TNFRSF1B, E2F7, SH2B1, IL2RB, TNFSF11, BTC, BTK, RACGAP1, CCR1, PTK2, RGL4, CD24, RGL1, BRCA2, CCR9, CCR6, CD36, SPTAN1, CCR2, LAT2, MC3R, KIT, PCNA, GNAI2, RAMP1, CELSR1, CCRL2, PDGFRB, DOK3, PSEN2, RASGRP4, GH1, GHR, GRM5, EPS8L1, EGF, TEK, CYFIP1, STMN1, ADCY9, LGALS12, PLK2, CDKN1A, NFAM1, CIT, HBEGF, GSN, IL5RA, SLC8A1, FGF5, PYCARD, GRAP2, STK32B, LHCGR, MAP2K2, DGKZ, NRBP1, RAB32, MELK, CALCRL, DHCR24, BCL6, CNOT3, CSPG4, LAT, TREM1, CX3CR1, EDNRB, PPP2R1A, CHEK1, PTGDR, SIK1, CCR10, PRL, RALGPS2, MAP4K1, RHOG, AVPR1A, TLR8, TLR7, RHOU, SGK1, TLR4, PTGER2, CXCR5, CXCR4, CXCR1, CXCR2, PDPN, MLH1, CAMK4, SIPA1, TSC2, ATP1B1, CSF2RB, ADRB2, TGFB1, SELE, DOCK5, MCTP1, CXCL1, TMEM100, BLNK, PTGIR, TGFBR3, NCAM1, TSHR]
GO:1902042;negative regulation of extrinsic apoptotic signaling pathway via death domain receptors;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;425.73912115989816;6.193554689224359;0.014249105244888325;0.731979686697602;[HMGB2, FASLG, TNFRSF10B]
GO:0035793;positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway;11.0;1.0;0.9324289523296623;9.628524252492122;462.90611455550015;8.67846133901236;0.015493051065716704;0.8762458687964789;[PDGFRB]
GO:1904343;positive regulation of colon smooth muscle contraction;10.0;1.0;0.9152410118609203;9.628524252492122;112.16807620771051;9.777073627680469;0.00375416456595737;0.9152410118609203;[KIT]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[CDA, KCNG2, TCL1A, TNFSF11, OLFM4, CLDN3, BLM, MGST1, CD79B, CD79A, NACC2, CAV1, CD3G, CD3E, KCND2, ARG1, NUP54, ACPP, FBP1, COLEC12, NLGN1, HM13, NLRC4, SAMHD1, RAD51, P2RX1]
GO:1904349;positive regulation of small intestine smooth muscle contraction;10.0;1.0;0.9152410118609203;9.628524252492122;112.16807620771051;8.67846133901236;0.00375416456595737;0.8590579283277371;[GHSR, KIT]
GO:1904469;positive regulation of tumor necrosis factor secretion;10.0;1.0;0.9152410118609203;9.628524252492122;775.9675723657698;7.292166977892469;0.025970936321606315;0.7881627702307852;[ORM1, FZD5, LRRK2, HAVCR2]
GO:0042542;response to hydrogen peroxide;5.0;0.9326813400603323;0.7565816818910864;9.541512875502493;79.2907140195247;5.09494240055625;0.0026537888412237636;0.5507966031644187;[HP, SLC8A1, IL18RAP, MYB, PDGFRB, DUSP1, ARG1, ADAM9, PCNA, FOXO1, SDC1, EZH2]
GO:1900425;negative regulation of defense response to bacterium;7.0;0.7671156992804218;0.7344772148974115;9.265618758802754;222.83389978997275;7.9853141584524145;0.0074580500884805735;0.7592887026755414;[HAVCR2]
GO:0002652;regulation of tolerance induction dependent upon immune response;7.0;0.6913464685778243;0.6965925995461126;9.117698628726131;69.78820826809242;8.67846133901236;0.002335748525423278;0.7947362817240173;[CD274, HAVCR2]
GO:1900426;positive regulation of defense response to bacterium;7.0;0.7671156992804218;0.7344772148974115;9.265618758802754;222.62122828472002;7.57984905034425;0.007450932164591693;0.738553198190834;[HAVCR2]
GO:0032715;negative regulation of interleukin-6 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;64.96654663153603;6.166155715036245;0.002174371849661483;0.6384578026126634;[ORM1, HAVCR2, GHSR, NLRP12, BANK1, BPI, TLR4]
GO:0032956;regulation of actin cytoskeleton organization;7.0;0.559792591703537;0.630815661108969;7.718981747607684;34.11626247365944;3.9689311377000256;0.0011418406023505395;0.553890688213353;[CYFIP1, CELSR1, CTGF, PYCARD, STMN1, PDGFRB, MEF2C, PFN1, EPHA3, TACSTD2, CORO1A, STAP1, TGFB1, BST1, NOX4, NRP1, ARHGEF10L, ARHGAP6, SPTAN1, RHOG, CIT, TMEFF2, RHOU, LRP1, EPS8L1, FLNA, JAM3, GSN, TEK]
GO:0071880;adenylate cyclase-activating adrenergic receptor signaling pathway;10.0;0.8259837884571596;0.8282329060895002;9.446202695698167;86.62055693168666;6.641579411751319;0.00289911208706348;0.7548916918429109;[ADCY9, ADRB2]
GO:0002769;natural killer cell inhibitory signaling pathway;8.0;1.0;0.875;9.628524252492122;130.16139686502353;9.083926447120524;0.004356384815420379;0.839552420951524;[CLEC12B, KIR2DL1]
GO:2000521;negative regulation of immunological synapse formation;8.0;1.0;0.875;9.628524252492122;159.58048984171964;9.083926447120524;0.005341015381885652;0.839552420951524;[LGALS3, HAVCR2]
GO:0035789;metanephric mesenchymal cell migration;7.0;1.0;0.8509193652572005;9.628524252492122;22.41982222863266;9.777073627680469;7.503712734623007E-4;0.8509193652572005;[PDGFRB]
GO:0034699;response to luteinizing hormone;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;100.64317762475399;8.390779266560578;0.0033684365821211493;0.7800242071602487;[TGFBR3, LHCGR]
GO:0010820;positive regulation of T cell chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;1408.745447987039;7.379178354882098;0.04714944235553481;0.8098004765652196;[TNFSF14, CCR2]
GO:0032712;negative regulation of interleukin-3 production;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;64.96654663153603;9.777073627680469;0.002174371849661483;0.8231203125901445;[HAVCR2]
GO:0043406;positive regulation of MAP kinase activity;12.0;0.7043150770688792;0.8002778511245842;9.369013057007038;2605.6877929993507;4.201124524534153;0.08721002546492271;0.6629660161470909;[, PROK2, TNFSF11, PDGFRB, MAP2K2, F2R, ADAM9, C5AR1, FPR1, TGFA, TNFRSF11A, IQGAP3, PDGFC, ELANE, DRD4, TGFB1, FZD5, GH1, NOX4, CSPG4, CD24, EZH2, LRRK2, GHR, MAP4K1, DUSP6, KIT, TLR4, CXCR4, EGF, PKN1]
GO:0040015;negative regulation of multicellular organism growth;6.0;1.0;0.8231203125901445;9.628524252492122;145.8359341853073;7.379178354882098;0.004880997473362539;0.7004918368257019;[ADRB2]
GO:0055074;calcium ion homeostasis;8.0;0.6302958089695718;0.6901479044847859;8.465373442686442;72.15273857439408;3.748795107449771;0.0024148872268360765;0.5667135561317821;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, TNFSF11, PTGDR, F2R, ATP1B1, AGTR1, C5AR1, FPR1, TMTC2, FPR3, FPR2, CD19, HRH4, ELANE, CCR10, DRD4, CCR1, TGFB1, WFS1, CAV1, CD24, GPR18, ATP2A3, FASLG, GRM5, CCR9, CCR6, CD36, CCR2, TRPC7, CD52, PTGIR, TRPC1, AVPR1A, CX3CR1, SLC24A1, SLC24A4, PTGER2, CXCR5, CXCR4, CXCR1, SV2A, CXCR2, S1PR3, GPR157, TMEM64, GPR6, P2RX5, CD4, GRINA, F2RL3]
GO:0034695;response to prostaglandin E;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;134.30653146733928;6.599019797332524;0.004495118740180942;0.6883935445785896;[PTGER2, TGFBR3, P2RY6, AKT1, PTGDR]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[SPINT2, MEF2C, SPINT1, BTK, SFN, LYN, BCL11B, FZD5, CDC6, NOX4, CDKN1A, TNFRSF13B, PRL, PTPRK, BRCA2, CD33, HAVCR2, DUSP1, ARG1, PAWR, PDCD1LG2, CEACAM1, TLR2, PTGS2, GPNMB, PDPN, CDKN2C, LILRB1, LILRB2, PKN1, CDH5, DACH1, F2R, TSC2, HGS, CD274, NACC2, IGFBP7, TGFB1, RARRES3, CAV1, HMGA1, DHCR24, INHBA, BCL6, OGN, CXCL1, NUP62, PTGIR, TGFBR3, DLL1, E2F7, CD9, FCGR2B]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, TFRC, MYB, AKT1, PROK2, MEF2C, CLDN7, AGTR1, ATF3, HHLA2, IQGAP3, PDGFC, ELANE, LYN, CDC6, CDKN1A, HLA-DPA1, HAVCR2, ARG1, FCRL3, MMP12, HBEGF, PTAFR, PTGS2, EPCAM, FLNA, IL12RB2, LRG1, HLA-DPB1, CHRM1, CTGF, FGF5, PYCARD, CDH3, F2R, MSH6, CD274, BLM, CALCRL, TNFRSF11A, CORO1A, NACC2, BCL6, FASLG, CX3CR1, KLF5, TCL1A, EDNRB, SKP2, ICOSLG, RUNX2, BTC, TGFA, EGR1, EGR3, TNFSF12, PTK2, BST1, CD28, CD24, NRP1, NRP2, PRL, CD3E, CCR2, RHOG, PDCD1LG2, AVPR1A, CEACAM6, KIT, GNAI2, CXCR2, LILRB2, IL6R, PDGFRB, GHSR, CCNE1, PRTN3, C5AR1, LTBP3, TGFB1, NR4A1, HMGB2, LAMC2, GLP2R, MMP9, TGFBR3, LTF, DLL1, S1PR3, EGF, MEIS2, TSHR, CD4, TEK]
GO:0051271;negative regulation of cellular component movement;5.0;0.5470854108181258;0.5637837172699831;7.364160372318274;52.38761662992485;4.128099389519264;0.001753366382809582;0.5013522066171892;[SPINT2, DACH1, MEF2C, ACTN1, ACTN4, PADI2, KCNE3, TACSTD2, KLRK1, STAP1, TGFB1, JAG1, JUP, GPR18, NRP1, PTPRR, MCTP1, PTPRK, ARAP3, TGFBR3, TMEFF2, ENG, CX3CR1, LRP1, SEMA4B, TIE1, CD9]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, PID1, SPIB, MYB, AKT1, MEF2C, ATF3, JAG1, JUP, FZD5, PAX5, MMP12, ENG, EPCAM, NR1H2, ATAD2, GTF2H1, PLXND1, FOXO1, MAFF, CIITA, HHEX, CEBPE, E2F5, E2F7, KLF5, POU2AF1, CCNH, TNFSF11, SLC11A1, EBF1, RUNX2, BEX1, EGR1, EGR2, EGR3, BCL11B, CD28, PRL, TLR4, TLR2, LILRB1, ARID4A, ADRB2, NLRP3, TGFB1, HMGA1, INHBA, NR4A2, NR4A1, TCF4, HMGB2, SLC40A1, ARHGEF10L, CKAP2, DLL1, MEIS2]
GO:0043525;positive regulation of neuron apoptotic process;8.0;0.8436909121759173;0.7968454560879586;9.392135474427892;179.36331192335928;5.885253329569843;0.0060031286335741505;0.6759721289664703;[FASLG, MYB, UBE2M]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[MYB, AKT1, SKP2, IL6R, PDGFRB, MMP9, HBEGF, CALCRL, PTAFR, PTGS2, GNAI2, ELANE]
GO:0071670;smooth muscle cell chemotaxis;7.0;1.0;0.8509193652572005;9.628524252492122;55.63348935964576;9.083926447120524;0.0018620028219775377;0.8154717862087246;[PDGFRB]
GO:0032703;negative regulation of interleukin-2 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.7325511899570465;0.002184000309729388;0.6674232935401965;[LAG3, HAVCR2]
GO:0002859;negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target;10.0;1.0;0.9152410118609203;9.628524252492122;1230.9351562269924;9.083926447120524;0.04119829190919933;0.8797934328124444;[CEACAM1, HAVCR2]
GO:0071799;cellular response to prostaglandin D stimulus;8.0;1.0;0.875;9.628524252492122;436.89110353785946;8.16763571524637;0.01462235205894615;0.7926932703116032;[PTGDR]
GO:0015804;neutral amino acid transport;9.0;0.620063164412167;0.7062722073863725;8.558082840790709;67.63036776559719;6.113511981550823;0.002263527545735134;0.7088859122241795;[SLC36A1, SLC6A15, SLC7A5, SLC7A8]
GO:2001189;negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell;9.0;1.0;0.896240625180289;9.628524252492122;430.8793777811617;8.67846133901236;0.014421145008071396;0.8400575416471059;[LGALS3, LILRB1, HAVCR2]
GO:0030644;cellular chloride ion homeostasis;9.0;1.0;0.896240625180289;9.628524252492122;141.59530137466902;8.390779266560578;0.004739067309512229;0.8253454670833372;[FASLG]
GO:0035655;interleukin-18-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.8311634786251565;0.00101047745553359;0.7514054297404357;[IL18RAP, ALOX5, AKT1, IL18R1]
GO:0030886;negative regulation of myeloid dendritic cell activation;7.0;1.0;0.8509193652572005;9.628524252492122;126.51759902192377;8.67846133901236;0.0042344301808169855;0.7947362817240173;[HAVCR2]
GO:0016579;protein deubiquitination;9.0;0.7307253602413294;0.7616033053009538;9.151600180401813;202.59641706362558;4.174954806800768;0.0067807197541817285;0.6097480081553338;[RUVBL1, SKP2, ADRB2, NLRP3, BARD1, FAM105A]
GO:0031295;T cell costimulation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;354.8971974647038;5.845247994956144;0.011878089812402261;0.6951668794741764;[CD274, HHLA2, CD3E, KLRK1, GRAP2, BTLA, AKT1, ICOSLG, LYN, TNFSF14, CAV1, PDCD1LG2, CD28, CD24]
GO:1901098;positive regulation of autophagosome maturation;9.0;1.0;0.896240625180289;9.628524252492122;490.39656958283985;7.8311634786251565;0.01641313185567848;0.7967266896635242;[ADRB2]
GO:0043410;positive regulation of MAPK cascade;10.0;0.6634067003016617;0.7469443620117512;9.174268980214526;1017.2390743488962;3.4929394666096676;0.03404607636272706;0.5938700986216354;[, PROK2, TNFSF11, EPHA3, FPR1, TGFA, FPR2, SLC30A10, IQGAP3, PDGFC, ELANE, CCR1, FZD5, MARCO, NOX4, CD24, EZH2, NRP1, CD36, HAVCR2, MAP4K1, GPR37, FCRL3, DUSP6, BANK1, KIT, TLR4, CXCR4, GNAI2, GPNMB, PKN1, CTGF, PYCARD, PDGFRB, MAP2K2, F2R, ADAM9, C5AR1, TNFRSF11A, ADRB2, DRD4, TGFB1, GH1, CSPG4, LRRK2, TREM2, GHR, CHI3L1, EGF, TIE1, CD4, LTBR, TEK, FCGR2B]
GO:0045954;positive regulation of natural killer cell mediated cytotoxicity;9.0;0.8653626801206646;0.8289219652406215;9.526741558182179;431.31665099041965;6.444869117505266;0.014435780148864921;0.7258315315665724;[LAG3, SH2D1A, IL18RAP, KLRK1]
GO:0090280;positive regulation of calcium ion import;9.0;0.8653626801206646;0.8289219652406215;9.420884887713877;92.69484377077161;6.8867018697843045;0.0031024130010644134;0.7484268790654467;[PDGFRB, LGALS3]
GO:0001541;ovarian follicle development;4.0;1.0;0.75;9.628524252492122;34.608406302298;6.166155715036245;0.001158312213394382;0.5653374900225189;[INHBA, KIT]
GO:0032815;negative regulation of natural killer cell activation;8.0;0.811012628672052;0.780506314336026;9.392135474427892;160.49678057359853;7.697632086000634;0.005371682808073518;0.7686572628545723;[HAVCR2]
GO:0050860;negative regulation of T cell receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.57973408832269;309.61561130321576;6.8867018697843045;0.010362555874359037;0.7271862538851576;[LGALS3, CEACAM1, PVRIG, PAWR, UBASH3A]
GO:1990830;cellular response to leukemia inhibitory factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[TFRC, TNFSF11, TLE4, PADI2, KLF5]
GO:0032496;response to lipopolysaccharide;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;64.414971589946;4.086714173356409;0.002155911129404774;0.4992357647380114;[PYCARD, EDNRB, GHSR, MEF2C, SLC11A1, CD180, F2R, KMO, SLPI, ADAM9, S100A8, CD274, ABCB4, C5AR1, MGST1, LY96, CSF2RB, TNFRSF11A, KLRK1, STAP1, NLRP3, ELANE, ABCA1, DEFA4, TNFRSF10C, TNFRSF10B, DEFA1, SELE, ALPL, HMGB2, CXCL1, TREM2, FASLG, CXCL2, CTSG, CD36, HAVCR2, PTGIR, ARG1, PDCD1LG2, TNFRSF1B, TLR4, CX3CR1, CEBPE, PTGER2, PTGS2, CNR1, IL12RB2, NR1H2, LILRB1, LILRB2, LTBR]
GO:0030512;negative regulation of transforming growth factor beta receptor signaling pathway;8.0;0.8933024483968273;0.8216512241984136;9.537552474286395;374.7458266990886;5.54296712308321;0.012542405570270547;0.6584675964488075;[TGFB1, CAV1, DNM2, TGFBR3]
GO:0030511;positive regulation of transforming growth factor beta receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;345.4564576873422;6.518977089658987;0.011562116748168153;0.7083807915285978;[TGFBR3, LRG1]
GO:0018108;peptidyl-tyrosine phosphorylation;9.0;0.811012628672052;0.801746939516315;9.414950152194063;338.33129968976414;4.530049555519983;0.011323644122215096;0.627907570118429;[IL5RA, SLA2, FGF5, GRAP2, PDGFRB, MAP2K2, BTC, MELK, BTK, EPHA3, BLK, CSF2RB, LYN, BMX, PTK2, GHR, KIT, HBEGF, IL12RB2, EGF, TIE1, WEE1, TEK]
GO:0060045;positive regulation of cardiac muscle cell proliferation;10.0;1.0;0.9152410118609203;9.628524252492122;720.414482973016;6.641579411751319;0.024111624414165377;0.7548916918429109;[TGFBR3, MEF2C]
GO:1905065;positive regulation of vascular smooth muscle cell differentiation;8.0;0.8653626801206646;0.8076813400603323;9.488762310116963;295.7578040146463;7.9853141584524145;0.009898747535627478;0.7833693374183408;[KIT, ENG]
GO:1902475;L-alpha-amino acid transmembrane transport;10.0;0.6181399273706679;0.7243109755462542;8.529911963824013;268.42115299878213;6.063501560976162;0.00898381442751516;0.7253287636709003;[SLC1A3, SLC7A11, SLC7A5, SLC7A7, SLC7A8, SLC17A6]
GO:0034154;toll-like receptor 7 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;8.390779266560578;0.013811191226989502;0.8772251544931927;[UNC93B1, TLR7, HAVCR2]
GO:0046777;protein autophosphorylation;8.0;0.7763722522362496;0.7631861261181248;9.31486669363708;180.75330000196035;4.488806596985934;0.006049650283656873;0.604557778120715;[SLA2, GRAP2, AKT1, PDGFRB, MAP2K2, VRK1, MELK, BTK, SIK1, BLK, LYN, BMX, PTK2, LRRK2, MAP4K1, KIT, CAMK4, TEK]
GO:0008542;visual learning;8.0;1.0;0.875;9.628524252492122;51.65827414420079;5.970411137910149;0.00172895594617802;0.6803271032452366;[MEIS2, ADAM2, KIT]
GO:0002320;lymphoid progenitor cell differentiation;5.0;0.8653626801206646;0.7229223519212526;9.223059144383958;22.164838071467113;7.379178354882098;7.418371831928127E-4;0.6676125360964777;[KIT]
GO:0043029;T cell homeostasis;7.0;1.0;0.8509193652572005;9.628524252492122;22.00128503895464;6.444869117505266;7.363632103827933E-4;0.6805102716434839;[TGFB1, SLC46A2, TNFSF14, CORO1A, SIT1]
GO:0098773;skin epidermis development;5.0;0.8933024483968273;0.736892236059334;9.474373572664863;33.122816977724916;9.083926447120524;0.0011085908756445111;0.7547934328124444;[DLL1]
GO:0010739;positive regulation of protein kinase A signaling;8.0;1.0;0.875;9.628524252492122;237.72454511224748;7.57984905034425;0.007956426586706367;0.7626338329336335;[ADRB2]
GO:0032526;response to retinoic acid;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;43.78950961223322;5.123113277522946;0.0014655954787213788;0.5522372631225753;[MYB, IGFBP7, LYN, ABCA1, PDGFRB, DUSP1, TIE1, EPHA3]
GO:0002315;marginal zone B cell differentiation;9.0;1.0;0.896240625180289;9.628524252492122;149.8071031872776;7.57984905034425;0.005013908926038414;0.7838744581139225;[DLL1]
GO:0097324;melanocyte migration;7.0;1.0;0.8509193652572005;9.628524252492122;24.971868181253015;9.083926447120524;8.357859548042604E-4;0.8154717862087246;[KIT]
GO:0045332;phospholipid translocation;8.0;1.0;0.875;9.628524252492122;116.86638763413639;6.641579411751319;0.003911412821194078;0.7146506799819907;[ABCA1, ATP8B4, ABCB4, ATP9A]
GO:0002318;myeloid progenitor cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;22.164838071467113;8.390779266560578;7.418371831928127E-4;0.7193458537639684;[KIT, JAM3]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[AKT1, TNFRSF1B, MMP9, POR, NLRC4, PTGS2, SFN, TNFSF14, TNFRSF10C, TNFRSF10B, DHCR24]
GO:0043032;positive regulation of macrophage activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;126.59742726208806;6.641579411751319;0.004237101960174532;0.6905700452391912;[ITGAM, LRRK2, STAP1, TLR4, HAVCR2]
GO:0032762;mast cell cytokine production;5.0;1.0;0.7902410118609202;9.628524252492122;22.637273805675832;9.083926447120524;7.576491820522217E-4;0.7547934328124444;[KIT]
GO:0055003;cardiac myofibril assembly;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;125.46400130584401;6.641579411751319;0.0041991672134361795;0.7146506799819907;[PDGFRB]
GO:0006919;activation of cysteine-type endopeptidase activity involved in apoptotic process;13.0;0.9326813400603323;0.9288956347978027;9.604426700913061;734.4853933519539;5.322726331426962;0.024582565121551242;0.7347594368888992;[FASLG, PYCARD, F2R, S100A8, NLRC4, NLRP3, TNFRSF10B, NLRP12, P2RX1]
GO:0050910;detection of mechanical stimulus involved in sensory perception of sound;6.0;1.0;0.8231203125901445;9.628524252492122;83.9288867027761;7.379178354882098;0.0028090243068477775;0.7004918368257019;[KIT]
GO:0071848;positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling;12.0;1.0;0.9481203125901445;9.628524252492122;1209.056277553609;9.083926447120524;0.04046602552971364;0.9126727335416687;[TNFSF11, TNFRSF11A]
GO:0034260;negative regulation of GTPase activity;6.0;1.0;0.8231203125901445;9.628524252492122;61.14468506277762;5.970411137910149;0.0020464575824072424;0.6284474158353811;[LRRK2, KLRK1]
GO:0035234;ectopic germ cell programmed cell death;5.0;1.0;0.7902410118609202;9.628524252492122;49.330608194382684;7.9853141584524145;0.001651051061600959;0.6986103492792611;[KIT]
GO:0032088;negative regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.61713652769816;5.420364800990877;0.009358533920496976;0.725318020585559;[PYCARD, HAVCR2, NLRP3, NLRP12, CCDC22]
GO:0046666;retinal cell programmed cell death;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;29.711636272016438;9.083926447120524;9.944217272877711E-4;0.7547934328124444;[FASLG]
GO:1900746;regulation of vascular endothelial growth factor signaling pathway;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;69.03899383076448;7.212124270218933;0.0023106729924551295;0.6919486831672181;[DLL1]
GO:0030217;T cell differentiation;6.0;0.657518819034173;0.651879722107231;8.679443697794976;65.04859315339479;5.132682728539097;0.00217711787291102;0.5856059460217904;[CD3G, CD3E, CCR9, CCR6, RUNX2, CLEC4D, KIT, BLM, EGR1, TGFB1, BCL11B, FZD5, BMX, CD4, CD28, GPR18, IL18R1]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[EHMT2, SLA2, AKT1, MEF2C, ATF3, IQGAP3, PKIG, EZH2, MMP12, FLNA, LGR4, GMNN, CTGF, FOXO1, CIITA, LRRK2, FASLG, HHEX, E2F7, KCNQ1, PCBP3, CCR1, EGR1, MSR1, CD28, PTPRK, CD3E, CD36, BANK1, CCNE1, CAV1, HMGA1, MXD1, HMGB2, FBP1, MYB, ELANE, BARD1, NDFIP2, CDKN1A, HAVCR2, PAWR, PAX5, AES, ENG, NR1H2, DACH1, TLE4, MAP2K2, NACC2, WFS1, BCL6, CNOT3, CR1, RFC1, NLRC4, RBBP8, KLF8, KLF5, ZNF608, EDNRB, PPP2R1A, IL1R2, RUNX2, BCL11A, IFNA2, XPO1, MLH1, ARID4A, BASP1, TGFB1, CBX4, NR4A2, MEIS2]
GO:0032516;positive regulation of phosphoprotein phosphatase activity;10.0;0.8653626801206646;0.8479223519212526;9.5525383455142;1089.2705050571928;6.832634648514029;0.036456903524454846;0.7646622655359331;[PDGFRB, FCRL3]
GO:0030218;erythrocyte differentiation;5.0;0.8436909121759173;0.712086467948879;9.117698628726131;22.675663695230284;5.885253329569843;7.589340571069517E-4;0.5912131408273906;[LYN, INHBA, TGFBR3, KIT, ACIN1]
GO:0002327;immature B cell differentiation;7.0;0.8436909121759173;0.7727648213451592;9.420884887713877;65.04859315339267;8.16763571524637;0.002177117872910949;0.7686126355688037;[KIT]
GO:0072014;proximal tubule development;8.0;0.8653626801206646;0.8076813400603323;9.36615998802463;58.05347923817328;8.390779266560578;0.001942997705362361;0.8041048419030481;[DLL1]
GO:0010628;positive regulation of gene expression;6.0;0.4705935272257725;0.5584170762030307;6.666693530613812;58.797024432214236;2.2471302570788807;0.001967883493859682;0.43803865843940215;[PID1, SPIB, AKT1, MEF2C, PADI2, ATF3, IQGAP3, JAG1, JUP, AZU1, MMP12, PTAFR, ATAD2, LGR4, CTGF, BLM, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, TNFSF11, EGR1, EGR2, EGR3, CD28, BRCA2, CD3E, CD36, KIT, CCNE1, CAV1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, PSRC1, CREB5, EGF, CD4, RAN, EHF, MYB, NUP85, NFE2, FZD5, PAWR, PAX5, ENG, EPCAM, GSN, NR1H2, GTF2H1, PLP1, PLXND1, CDH3, CDH1, MAP2K2, F2R, ADAM2, MAFF, RFC1, CEBPE, KLF5, CHEK1, SLC11A1, EBF1, RUNX2, BEX1, BCL11B, IFNA2, PRL, RHOG, TLR4, TLR2, LILRB1, CAMK4, ARID4A, HGS, ADRB2, STAP1, NLRP3, TGFB1, NR4A2, NR4A1, SLC40A1, CKAP2, DNM2, DLL1, MEIS2]
GO:0016042;lipid catabolic process;4.0;0.5127202928476964;0.5063601464238482;6.883086519318291;43.14795622097559;4.114113147544524;0.0014441232640765526;0.4603959376912539;[ABHD12, SLC27A2, PLD4, PLA2G7, RARRES3, CYP4F2, CYP4F3, SRD5A3, PNPLA6]
GO:0034138;toll-like receptor 3 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;7.474488534686424;0.013811191226989502;0.8303660038532719;[COLEC12, UNC93B1, HAVCR2]
GO:0010863;positive regulation of phospholipase C activity;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;83.73920694943958;6.139487467954083;0.0028026758962042993;0.6889736746265369;[PDGFRB, C5AR1, PTAFR, AVPR1A, SELE, RASGRP4, KIT]
GO:0070757;interleukin-35-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.379178354882098;0.00101047745553359;0.728290889492758;[IL12RB2]
GO:0050921;positive regulation of chemotaxis;6.0;0.6417349323569144;0.6439877787686017;8.362857879160845;97.3409382187974;4.886724499458715;0.003257913601026301;0.5730276307483924;[NRP1, CXCL1, CXCL2, C3AR1, CCR6, IL6R, CCR2, PDGFRB, SUCNR1, C5AR1, FPR2, PLA2G7, CXCR2, CCR1, TGFB1, TNFSF14, AZU1]
GO:0032753;positive regulation of interleukin-4 production;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;64.94897299966192;6.686031174322154;0.0021737836760178982;0.665044257777226;[PRG2, CD3E, CD28, NLRP3, HAVCR2]
GO:0030336;negative regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.20713857156096;158.04059951544355;4.3090134865453384;0.00528947663847651;0.5712825153487487;[DACH1, MEF2C, PADI2, TACSTD2, KLRK1, STAP1, TGFB1, JAG1, JUP, GPR18, PTPRR, MCTP1, PTPRK, ARAP3, TMEFF2, ENG, CX3CR1, LRP1, TIE1]
GO:0030335;positive regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.22453031427283;157.26390226612122;3.6656062881777913;0.005263481280523835;0.5383786413027378;[LGALS3, C3AR1, AKT1, IL1R1, ACTN4, PFN1, FPR2, PLA2G7, PDGFC, ELANE, LYN, CCR1, TNFSF14, PLK2, PTK2, NOX4, NRP1, NRP2, CCR6, CCR2, ANXA3, GAB1, CEACAM6, KIT, HBEGF, PTAFR, PTGS2, GNAI2, GPNMB, CXCR2, PDPN, FLNA, SLC8A1, CXCL16, PYCARD, IL6R, PDGFRB, F2R, ADAM9, CD274, CD151, C5AR1, CORO1A, TGFB1, DOCK5, TNFAIP6, LAMC2, CXCL1, CXCL2, MMP9, P2RY6, EGF, SEMA4B, TEK]
GO:0048170;positive regulation of long-term neuronal synaptic plasticity;10.0;1.0;0.9152410118609203;9.628524252492122;315.9495864907144;8.16763571524637;0.010574548323677036;0.8329342821725234;[KIT]
GO:0060981;cell migration involved in coronary angiogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;22.825287336738096;9.777073627680469;7.639418257356832E-4;0.8231203125901445;[PDGFRB]
GO:0042759;long-chain fatty acid biosynthetic process;9.0;0.7980440201809971;0.7952626352707877;9.372590878354922;458.549617088559;6.375876246018314;0.015347243016091356;0.722303232910233;[ELOVL6, PTGS2, ALOX5, PLP1]
GO:0001570;vasculogenesis;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;5.6339389012889365;7.050676185779127E-4;0.5381198974168686;[GJC1, TMEM100, HHEX, TGFB1, CAV1, TIE1, PTK2, TGFBR3, ENG]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[EHMT2, SLA2, MYB, MEF2C, ATF3, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, NR1H2, DACH1, TLE4, FOXO1, NACC2, WFS1, BCL6, CIITA, FASLG, HHEX, RFC1, RBBP8, E2F7, KLF8, KLF5, ZNF608, EDNRB, PCBP3, EGR1, BCL11A, XPO1, CD36, CCNE1, TGFB1, CBX4, CAV1, NR4A2, MXD1, FBP1, MEIS2]
GO:0051466;positive regulation of corticotropin-releasing hormone secretion;10.0;1.0;0.9152410118609203;9.628524252492122;618.6408688355265;9.083926447120524;0.02070535313928978;0.8797934328124444;[TNFSF11]
GO:0009968;negative regulation of signal transduction;6.0;0.43649654099988644;0.5413685830900877;6.680044863788677;140.65047919891595;2.686163805600486;0.0047074449615745265;0.460490854527945;[, PID1, SLA2, STMN1, AKT1, UBASH3A, PADI2, ATF3, FLRT2, FIGNL1, LYN, EZH2, LRRC4, DUSP2, DUSP1, ARG1, FCRL3, PAWR, DUSP6, AES, MMP12, LRRC19, PTGS2, NR1H2, TMEM64, SULF2, LGR4, PYCARD, TLE4, LY96, FOXO1, WFS1, TNFRSF10B, PTPRE, BCL6, CCDC22, LRRK2, FASLG, HHEX, PVRIG, CX3CR1, LRP1, TIE1, LGALS3, PPP2R1A, IL1R2, RUNX2, SIK1, EPHA3, APCDD1, EGR1, VNN1, NRP1, PTPRR, CD3E, CEACAM1, BANK1, KIT, TLR4, GNAI2, NLRP12, GRINA, RGS1, PDGFRB, TSC2, HGS, ADRB2, STAP1, NLRP3, TGFB1, CAV1, NR4A2, HMGB2, LRRTM4, NUP62, PTGIR, ARAP3, MMP9, DNM2, TGFBR3, FBP1, LTF, CLEC12B, EGF, TEK]
GO:0048863;stem cell differentiation;4.0;0.7043150770688792;0.6021575385344395;8.242229891372231;21.066225782797595;5.734022359845919;7.050676185779127E-4;0.5432381701418294;[HHEX, EPCAM, MEF2C, ACE, RUNX2, KIT]
GO:0035338;long-chain fatty-acyl-CoA biosynthetic process;8.0;1.0;0.875;9.628524252492122;500.3176215265477;6.8867018697843045;0.016745180535867314;0.7271862538851576;[ACSL1, TECR, ELOVL6]
GO:0070301;cellular response to hydrogen peroxide;6.0;1.0;0.8231203125901445;9.628524252492122;361.02555909653125;5.682729065458369;0.012083200561052132;0.6137353412716126;[PCNA, FOXO1, IL18RAP, MYB, ARG1, EZH2]
GO:2000573;positive regulation of DNA biosynthetic process;8.0;0.7980440201809971;0.7740220100904985;9.427853557029971;748.2879117532506;5.618190544320798;0.02504452299098255;0.6623145257091445;[RFC5, PDGFRB, RFC3, RFC4, RFC2, NOX4]
GO:0031532;actin cytoskeleton reorganization;6.0;1.0;0.8231203125901445;9.628524252492122;32.01253927882412;5.788089581116195;0.001071430880247358;0.6191234829421188;[NRP1, FLNA, CXADR, GAB1, KIT]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[SPIB, MEF2C, ATF3, EZH2, CHAF1B, FLNA, ZNF467, ATAD2, PKN1, RUVBL1, FOXO1, CIITA, FASLG, HHEX, E2F5, E2F7, POU2AF1, CCNH, BTK, EGR1, EGR2, EGR3, HMGA1, MXD1, HMGB2, AFF3, NUP62, CREB5, EHF, HOXA9, MYB, NFE2, ZNF367, BRD2, PAWR, PAX5, AES, GTF2H1, TLE4, NACC2, BCL6, CNOT3, MAFF, RFC1, CEBPE, KLF8, KLF5, ZNF608, EBF1, BCL11B, BCL11A, ARID4A, C5AR1, NLRP3, CBX4, NR4A2, LTF, MEIS2]
GO:0051480;regulation of cytosolic calcium ion concentration;10.0;0.6634067003016617;0.7469443620117512;9.01761517016915;288.6919123283276;4.053488525728088;0.009662258499776054;0.6225366035731486;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, PTGDR, F2R, AGTR1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, CCR10, CCR1, CAV1, CD24, GPR18, FASLG, GRM5, CCR9, CCR6, CD36, CCR2, TRPC7, CD52, PTGIR, TRPC1, AVPR1A, CX3CR1, PTGER2, CXCR5, CXCR4, CXCR1, CXCR2, S1PR3, GPR157, TMEM64, GPR6, P2RX5, CD4, F2RL3]
GO:0042761;very long-chain fatty acid biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;456.7578576193329;7.212124270218933;0.01528727443913519;0.7650689957573628;[ELOVL4, TECR, ELOVL6]
GO:0060979;vasculogenesis involved in coronary vascular morphogenesis;5.0;1.0;0.7902410118609202;9.628524252492122;21.75937296335754;8.67846133901236;7.282666309192915E-4;0.7340579283277371;[TGFBR3]
GO:0038162;erythropoietin-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;8.390779266560578;0.00101047745553359;0.7800242071602487;[KIT]
GO:0002551;mast cell chemotaxis;8.0;1.0;0.875;9.628524252492122;95.22538104108446;8.16763571524637;0.0031871078061660985;0.7926932703116032;[KIT]
GO:0060853;Notch signaling pathway involved in arterial endothelial cell fate commitment;7.0;1.0;0.8509193652572005;9.628524252492122;28.581916314885376;9.777073627680469;9.566110170045473E-4;0.8509193652572005;[DLL1]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, PTGDR, F2R, AGTR1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, CCR10, CCR1, CAV1, CD24, GPR18, FASLG, CCR9, CCR6, CD36, CCR2, CD52, PTGIR, TRPC1, AVPR1A, CX3CR1, PTGER2, CXCR5, CXCR4, CXCR1, CXCR2, S1PR3, GPR157, GPR6, P2RX5, CD4, F2RL3]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[PID1, EHMT2, SLA2, SPIB, AKT1, MEF2C, ATF3, JAG1, JUP, PKIG, EZH2, MMP12, PTAFR, ZNF467, ATAD2, PKN1, RUVBL1, MAZ, FOXO1, CIITA, FASLG, HHEX, E2F5, E2F7, POU2AF1, CCNH, TNFSF11, TGFA, PCBP3, EGR1, EGR2, EGR3, CD28, CD36, KIT, NR3C2, CCNE1, CAV1, HMGA1, INHBA, TCF4, MXD1, HMGB2, ARHGEF10L, FBP1, CREB5, EHF, HOXA9, MYB, ELANE, NFE2, FZD5, CDKN1A, ZNF367, HAVCR2, BRD2, PAWR, PAX5, AES, ENG, EPCAM, NR1H2, GTF2H1, PLXND1, DACH1, TLE4, NACC2, WFS1, BCL6, MAFF, RFC1, CEBPE, RBBP8, KLF8, KLF5, PPIL4, ZNF608, EDNRB, CHEK1, SLC11A1, EBF1, RUNX2, PFN1, BEX1, BCL11B, BCL11A, PRL, XPO1, TLR4, TLR2, LILRB1, ARID4A, ADRB2, NLRP3, TGFB1, CBX4, NR4A2, NR4A1, SLC40A1, TMEM100, CKAP2, TGFBR3, DLL1, MEIS2]
GO:0030316;osteoclast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;47.07409398820286;6.375876246018314;0.0015755275618510598;0.6491829203200885;[TGFB1, TFRC, TREM2, TNFRSF11A, OSCAR, TNFSF11]
GO:0031649;heat generation;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;21.014590666490108;7.697632086000634;7.033394377036888E-4;0.7167775754447168;[ADRB2]
GO:0030318;melanocyte differentiation;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;22.857985252022832;6.8867018697843045;7.650361955340501E-4;0.6424272657460779;[MEF2C, EDNRB, KIT]
GO:0002548;monocyte chemotaxis;7.0;1.0;0.8509193652572005;9.628524252492122;125.46101547564297;6.039404009397101;0.004199067280386423;0.6597747671587765;[TNFRSF11A, LGALS3, TNFSF11, IL6R, CCR2]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[AKT1, PROK2, MEF2C, CLDN7, SLC30A10, FIGNL1, SFN, BARD1, PLK2, AZU1, CDKN1A, CHL1, DUSP1, ANXA5, PTGS2, UNG, FLNA, GABRA5, CLEC5A, F2R, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, TNFRSF10B, DHCR24, BCL6, LRRK2, FASLG, TNFRSF1B, ADAMTS20, CX3CR1, LRP1, NLRC4, TIE1, IL2RB, SLC46A2, LGALS3, TCL1A, EDNRB, BTC, POR, EPHA3, EGR3, BCL11B, TNFSF14, PTK2, VNN1, CD28, NRP1, CEACAM6, KIT, GNAI2, CXCR2, PDPN, LILRB1, GRINA, PDGFRB, GHSR, C5AR1, PSEN2, CBX4, CAV1, NR4A2, HMGB2, SLC40A1, NUP62, MMP9, LTF, DLL1, TEK]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CX3CR1, CXCR5, CXCR4, CXCL1, CXCL2, CXCR1, CXCR2, CCRL2, CCR9, CCR6, CCR10, CCR2, CCR1]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[MYB, AKT1, MEF2C, ATF3, SFN, BARD1, LYN, NOX4, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD4, GSN, BIK, G0S2, CTGF, PYCARD, F2R, MELK, MAL, S100A8, CD274, FOXO1, NACC2, TNFRSF10B, BCL6, FASLG, NLRC4, P2RX1, PPP2R1A, SIK1, TNFSF12, ITM2C, CXCR2, SORT1, LILRB1, PPP1CA, NLRP12, PDGFRB, NLRP3, TGFB1, CAV1, INHBA, UBE2M, MMP9, DNM2, CNR1, LTBR]
GO:0042098;T cell proliferation;6.0;0.7248374789738407;0.6855390520770648;9.081980546124052;51.294476028837884;6.343086423195323;0.0017167799506538708;0.647506047256038;[CD151, TNFSF14, SLC11A1, LILRB1]
GO:0032732;positive regulation of interleukin-1 production;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;65.64212018022187;6.063501560976162;0.0021969826883592772;0.6332080644001243;[ORM1, PYCARD, NLRP3, HAVCR2, EGR1, FZD5, AZU1, NLRP12, IGHD, TLR8, TLR4]
